AR043850A1 - Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos - Google Patents
Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativosInfo
- Publication number
- AR043850A1 AR043850A1 ARP040101216A ARP040101216A AR043850A1 AR 043850 A1 AR043850 A1 AR 043850A1 AR P040101216 A ARP040101216 A AR P040101216A AR P040101216 A ARP040101216 A AR P040101216A AR 043850 A1 AR043850 A1 AR 043850A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- substituents
- alkoxy
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a derivados de ácidos hidroxámicos y a su uso en el tratamiento de trastornos hiperproliferativos. Reivindicación 1: Un compuesto de fórmula (1) en el cual W se selecciona de H, alquilo (C1-6), O-fenilo sustituido opcionalmente con hasta 2 sustituyentes, cada uno seleccionado independientemente de R12, fenilo sustituido opcionalmente con hasta 2 sustituyentes cada uno seleccionado independientemente de R12, OH, COOR7, C(O)NHR7, S(O)2-alquilo(C1-3),NHS(O)2-alquilo(C1-3), N[alquilo(C1-3)]2, NH-alquilo(C1-3), NHC(O)-alquilo(C1-3), el resto de fórmula (2) y alcoxi(C1-3) sustituido con 1 sustituyente seleccionado de N-[alquilo(C1-3)]2, NH-alquilo(C1-3) y el resto de fórmula (2), indolilo sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de R12, OH, C(O)O-alquilo(C1-4), alquilo(C1-3) sustituido con 1 o 2 sustituyentes, cada uno seleccionado independientemente de OH, C(O)R8, alcoxi(C1-3), pirrolidinilo, resto de fórmula (2), imidazolilo, NH-alquilo (C1-3), y n[alquilo(C1-3)[2 y alcoxi(C1-3) sustituido con 1 sustituyente seleccionado de NH-alquilo(C1-3), N[alquilo(C1-3)]2, pirrolidinilo, imidazolilo, resto de fórmula (2) y alcoxi (C1-3), y otro heteroarilo sustituido opcionalmente con hasta 3 sustituyentes, cada uno seleccionado independientemente de R12; L se selecciona de CHR4, CHR5-CHR6 y CHR5-CH2-CHR6; R1 se selecciona de H, C(O)R10, C(O)OR7, tetrahidropiranilo, cicloalquilo (C3-6), fenilo sustituido opcionalmente con hasta 2 sustituyentes, cada uno seleccionado independientemente de R12, piridilo, sustituido opcionalmente con hasta 2 sustituyentes, cada uno seleccionado independientemente de R12, S(O)2-fenilo donde dicho fenilo está sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de R12, NH2, NHC(O)alquilo(C1-3), NH-alquil(C1-3)-N[alquilo(C1-3)]2, NHalquil(C1-3)-OH, COOH, OH, y alcoxi (C1-3) sustituido con 1 sustituyente seleccionado de N[alquilo(C1-3)]2, OH, y resto de fórmula (2), S(O)2-alquilo C1-3 sustituido opcionalmente con un anillo fenilo, alquilo(C1-6) sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de OR11, C(O)R10, C(O)OR7, N[alquilo(C1-3)]2, cicloalquilo(C3-6),dioxopirrolidinilo, resto de fórmula (2), glucopiranosilo, glucopiranosilamino, alcoxi(C1-3) sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de OH, resto de fórmula (2) e imidazolilo, O-fenilo sustituido opcionalmente con hasta dos sustituyentes, cada uno seleccionado independientemente de R12, NH2 en donde un H está opcionalmente reemplazado con un sustituyente seleccionado de S(O)2-alquilo(C1-3), S(O)2NH-alquilo(C1-3), S(O)CF3, C(O)R7, S(O)2N[alquilo(C1-3)]2, C(O)O-alquilo(C1-4), C(O)NH-alquilo(C1-4), C(O)N[alquilo(C1-3)]2,C(O)-resto de fórmula (2) y alquilo(C1-4) sustituido opcionalmente con un grupo OH, fenilo sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de R12, OH, S-alquilo(C1-3), C(O)NH2, S(O)2NH2, C(O)N[alquilo(C1-3)]2, S(O)2-alquilo(C1-3), S(O)2NHC(O)-alquilo(C1-3),C(O)alquilo(C1-3), C(O)NH-alquilo(C1-3), NHS(O)2-alquilo(C1-3), NHS(O)2N[alquilo(C1-3)]2, NHC(O)NH-alquilo(C1-3), NHC(O)N[alquilo(C1-3)]2, NHC(O)NH2, S(O)2N[alquilo(C1-3)]2, NHS(O)2NH-alquilo(C1-3), NHC(O)-alquilo(C1-3), S(O)2NH-alquilo(C1-3) sustituido opcionalmente con 1 sustituyente seleccionado de alcoxi(C1-3), NH-alquilo(C1-3), N[alquilo(C1-3)]2 y resto de fórmula (2), alquilo(C1-3) sustituido con un sustituyente seleccionado de NHS(O)2-alquilo(C1-3), NHS(O)2N[alquilo(C1-3)]2, NHC(O)NH-alquilo(C1-3), NHC(O)N[alquilo(C1-3)+2, NHS(O)2NH-alquilo(C1-3), y NHC(O)alquilo(C1-3) y alcoxi (C1-3) sustituido con 1 sustituyente seleccionado de OH, NH-alquilo(C1-3),N[alquilo(C1-3)]2, alcoxi(C1-3) y resto de fórmula (2), pirrolilo sustituido opcionalmente con un sustituyente seleccionado de R12, C(O)N[alquilo(C1-3)]2, C(O)NH-alquilo(C1-3), C(O)-alquilo(C1-3), C(O)-resto de fórmula (2) y S(O)2-alquilo(C1-3), pirazolilo sustituido opcionalmente con hasta 3 sustituyentes, cada uno seleccionado independientemente de R12, C(O)N[alquilo(C1-3)]2, C(O)NH-alquilo(C1-3), y C(O)-resto de fórmula (2) y otro heteroarilo sustituido opcionalmente con hasta dos sustituyentes, cada uno seleccionado independientemente de R12; R2 se selecciona en cada caso independientemente de alquilo(C1-3), halo, alcoxi (C1-3), CF3, NO2, NH2, CN, y COOH; R3 se selecciona de H, alquilo(C1-3) y halo; R4 se selecciona de H, alquil(C1-3)-OH; R5 se selecciona de H, OH y alquilo(C1-3); R6 se selecciona de H, C(O)OR7, C(O)R9 y alquilo(C1-6) sustituido opcionalmente con un sustituyente seleccionado de OH, NHS(O)2-alquilo(C1-3),y NHC(O)-alquilo(C1-3); R7 se selecciona de H y alquilo(C1-4); R8 se selecciona de OH, NH2, N[alquilo(C1-3)]2, morfolinilo y pirrolidinilo; R9 se selecciona de NH2, morfolinilo, N[alquilo(C1-3)]2 y NH-alquilo(C1-3) sustituido opcionalmente con un sustituyente seleccionado de OH, COOH y N[alquilo(C1-3)]2; R10 se selecciona de cicloalquilo(C3-6), morfolinilo, N[alquilo(C1-3)]2, alcoxi(C1-3), heteroarilo sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de alquilo(C1-3), alcoxi(C1-3), OH, halo y CF3, fenilo sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de alquilo(C1-3), alcoxi(C1-3), OH, halo y CF3, alquilo (C1-3) sustituido opcionalmente con un sustituyente seleccionado de fenilo, imidazolilo y resto de fórmula (2), NH-alquilo(C1-4) sustituido opcionalmente con 1 anillo fenilo sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de alquilo(C1-3), alcoxi(C1-3), halo y CF3, y NH-fenilo donde dicho fenilo está sustituido opcionalmente con 1 o 2 sustituyentes, cada uno seleccionado independientemente de alquilo(C1-3), alcoxi(C1-3), halo y CF3; R11 se selecciona de H, C(O)N[alquilo(C1-3)]2, C(O)-pirrolidinilo, C(O)NH-fenilo, y C(O)NH-alquilo(C1-3) sustituido opcionalmente con 1 anillo fenilo; R12 se selecciona de alquilo(C1-6), alcoxi(C1-3), halo, NO2, CN, CF3, O-CF3 y fenilo sustituido opcionalmente con hasta 2 sustituyentes, cada uno seleccionado independientemente de halo, alquilo(C1-3) y alcoxi(C1-3); X se selecciona de O, S, CH2 y NH, y cuando X es NH, el H en NH está sustituido opcionalmente con C(O)alquilo(C1-3), S(O)2-alquilo(C1-3), o alquilo(C1-6) y cuando X es O, S, o CH2, el resto de fórmula (2) está sustituido opcionalmente reemplazando cualquier átomo de H del resto de fórmula (2) con alquilo(C1-4); m se selecciona de 0, 1 y 2; n se selecciona de 1 y 2; la doble línea lisa y de punto superpuestas se selecciona de una unión doble y una unión simple; o una sal, un éster o un carbonato del mismo aceptables para uso farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46347903P | 2003-04-17 | 2003-04-17 | |
US48405303P | 2003-06-30 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043850A1 true AR043850A1 (es) | 2005-08-17 |
Family
ID=33313443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101216A AR043850A1 (es) | 2003-04-17 | 2004-04-12 | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20060063760A1 (es) |
EP (1) | EP1620397A1 (es) |
JP (1) | JP2006523722A (es) |
KR (1) | KR20060004943A (es) |
AR (1) | AR043850A1 (es) |
AU (1) | AU2004232987A1 (es) |
BR (1) | BRPI0409586A (es) |
CA (1) | CA2522565A1 (es) |
CL (1) | CL2004000810A1 (es) |
CO (1) | CO5630022A2 (es) |
EC (1) | ECSP056174A (es) |
MA (1) | MA27834A1 (es) |
MX (1) | MXPA05010800A (es) |
NO (1) | NO20055399L (es) |
PE (1) | PE20050139A1 (es) |
RU (1) | RU2005135486A (es) |
TW (1) | TW200508196A (es) |
WO (1) | WO2004094376A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY144970A (en) * | 2005-09-08 | 2011-11-30 | S Bio Pte Ltd | Heterocyclic compounds |
JP2007077085A (ja) * | 2005-09-15 | 2007-03-29 | Univ Of Tokyo | Hdac阻害活性を有する新規置換ヒドロキサム酸誘導体 |
CN101417967A (zh) * | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | 组蛋白去乙酰酶抑制剂、其组合物及其应用 |
CA2870430A1 (en) * | 2012-04-16 | 2013-10-24 | Toa Eiyo Ltd. | Polycyclic fused ring amino compounds |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0301861B1 (en) * | 1987-07-29 | 1992-04-01 | Takeda Chemical Industries, Ltd. | Cell proliferation inhibitors |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
JPH10182583A (ja) * | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | 新規ヒドロキサム酸誘導体 |
US20030199571A1 (en) * | 1999-12-24 | 2003-10-23 | Gordon Bruton | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
CA2461373A1 (en) * | 2001-11-06 | 2003-05-15 | Novartis Ag | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
US7495022B2 (en) * | 2002-04-11 | 2009-02-24 | Sk Chemicals Co., Ltd. | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
-
2004
- 2004-04-12 AR ARP040101216A patent/AR043850A1/es unknown
- 2004-04-15 CL CL200400810A patent/CL2004000810A1/es unknown
- 2004-04-16 TW TW093110582A patent/TW200508196A/zh unknown
- 2004-04-16 AU AU2004232987A patent/AU2004232987A1/en not_active Abandoned
- 2004-04-16 EP EP04759991A patent/EP1620397A1/en not_active Withdrawn
- 2004-04-16 BR BRPI0409586-3A patent/BRPI0409586A/pt not_active IP Right Cessation
- 2004-04-16 RU RU2005135486/04A patent/RU2005135486A/ru not_active Application Discontinuation
- 2004-04-16 WO PCT/US2004/011990 patent/WO2004094376A1/en active Application Filing
- 2004-04-16 CA CA002522565A patent/CA2522565A1/en not_active Abandoned
- 2004-04-16 KR KR1020057019640A patent/KR20060004943A/ko not_active Application Discontinuation
- 2004-04-16 US US10/554,390 patent/US20060063760A1/en not_active Abandoned
- 2004-04-16 PE PE2004000380A patent/PE20050139A1/es not_active Application Discontinuation
- 2004-04-16 MX MXPA05010800A patent/MXPA05010800A/es unknown
- 2004-04-16 JP JP2006513115A patent/JP2006523722A/ja active Pending
-
2005
- 2005-10-28 MA MA28573A patent/MA27834A1/fr unknown
- 2005-11-10 CO CO05114719A patent/CO5630022A2/es not_active Application Discontinuation
- 2005-11-15 NO NO20055399A patent/NO20055399L/no not_active Application Discontinuation
- 2005-11-17 EC EC2005006174A patent/ECSP056174A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0409586A (pt) | 2006-04-18 |
CL2004000810A1 (es) | 2005-02-11 |
TW200508196A (en) | 2005-03-01 |
US20060063760A1 (en) | 2006-03-23 |
CA2522565A1 (en) | 2004-11-04 |
RU2005135486A (ru) | 2006-05-10 |
AU2004232987A1 (en) | 2004-11-04 |
CO5630022A2 (es) | 2006-04-28 |
MA27834A1 (fr) | 2006-04-03 |
KR20060004943A (ko) | 2006-01-16 |
EP1620397A1 (en) | 2006-02-01 |
NO20055399L (no) | 2005-11-15 |
JP2006523722A (ja) | 2006-10-19 |
PE20050139A1 (es) | 2005-05-22 |
WO2004094376A1 (en) | 2004-11-04 |
ECSP056174A (es) | 2006-04-19 |
MXPA05010800A (es) | 2005-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20021399D0 (no) | Kazolinderivater og deres anvendelse som farmasöytika | |
AR043059A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos | |
AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
PE20061124A1 (es) | Compuestos y derivados de dibencil amina | |
YU21590A (sh) | Derivati benzokondenziranih, n vsebujočih heterociklov in postopek za njihovo pripravo | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
AR030230A1 (es) | Derivados de acilfenilurea, procedimiento para su preparacion y su empleo en la preparacion de medicamentos | |
CA2457054A1 (en) | Activator of peroxisome proliferator-activated receptor .delta. | |
AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
RU2007131274A (ru) | Замещенные пиразолопиридины, композиции, содержащие их, способ получения и применение | |
AR075731A1 (es) | Derivados heterociclicos de bencimidazoles, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento del virus sincicial respiratorio(vsr). | |
RS51743B (en) | MACROCYCLIC HEPATITIS VIRUS INHIBITORS C | |
MXPA03010584A (es) | Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas. | |
AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
AR055619A1 (es) | Diaminopirimidinas como moduladores p2x2/3 | |
AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
RS52451B (en) | PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE | |
AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
HRP20090264T1 (en) | Phenyl-piperazin methanone derivatives | |
AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
AR074604A1 (es) | Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano. | |
HRP20090050T3 (en) | Novel pyrrolidine-3,4-dicarboxamide derivatives | |
AR043850A1 (es) | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |